Table 1.
General characteristics of patients with pancreatic tumor according to cachectic state.
| Variable | Overall | No Cachexia | Cachexia | Cachexia | p |
|---|---|---|---|---|---|
| Without Inflammation | With Inflammation | ||||
| n | 62 | 13 | 26 | 23 | - |
| Male/Female (%) | 35/27 (56.5/43.5) | 6/7 (46.2/53.8) | 14/12 (53.8/46.2) | 15/8 (65.2/34.8) | 0.511 |
| Age (years) | 68.3 (63.1, 75.2) | 67.6 (61.4, 76.3) | 70.2 (63.2, 74.8) | 67.8 (64.9, 74.2) | 0.997 |
| Weight (kg) | 68.5 (58.7, 81.5) | 76.5 (68.0, 82.2) | 67.1 (56.5, 78.1) | 67.0 (59.0, 82.3) | 0.150 |
| BMI (kg/m2) | 24.4 (21.7, 26.8) | 26.9 (25.6, 28.3) | 23.5 (21.6, 26.1) † | 23.0 (20.7, 25.7) † | 0.015 |
| Weight loss percentage (%) | 7.2 (4,0, 12.2) | 1.9 (0.0, 3.0) | 9.7 (5.7, 12.7) † | 9.5 (7.3, 13.9) † | <0.001 |
| L3-IMAT (cm2) | |||||
| Male | 14.6 (7.2, 19.5) | 18.0 (10.3, 21.6) | 12.2 (6.3, 19.7) | 13.5 (7.4, 17.6) | 0.581 |
| Female | 9.7 (7.6, 19.2) | 13.9 (10.7, 18.4) | 8.1 (7.7, 22.3) | 7.7 (7.2, 13.6) | 0.292 |
| M-RA (HU) | |||||
| Male | 35.3 (30.8, 42.8) | 35.5 (33.7, 38.3) | 32.5 (29.4, 41.2) | 35.3 (32.5, 44.2) | 0.757 |
| Female | 37.4 (30.0, 40.7) | 37.4 (31.4, 40.0) | 35.6 (28.5, 40.9) | 36.8 (33.1, 41.6) | 0.843 |
| L3-SMI (cm2/m2) | |||||
| Male | 46.7 (41.7, 50.3) | 47.0 (45.6, 48.3) | 47.6 (43.2, 51.3) | 43.0 (40.3, 48.8) | 0.564 |
| Female | 36.1 (34.2, 42.5) | 38.9 (35.8, 42.7) | 36.7 (34.9, 42.5) | 35.1 (33.5, 39.4) | 0.665 |
| L3-VATI (cm2/m2) | |||||
| Male | 63.9 (33.4, 79.7) | 70.6 (66.3, 79.7) | 64.6 (31.8, 85.1) | 44.4 (30.5, 71.6) | 0.221 |
| Female | 28.9 (12.4, 47.7) | 39.7 (25.1, 48.8) | 29.0 (10.2, 49.4) | 28.7 (4.8, 37.3) | 0.446 |
| L3-SATI (cm2/m2) | |||||
| Male | 43.6 (31.6, 57.3) | 52.1 (39.8, 59.2) | 47.1 (34.8, 56.0) | 39.7 (27.1, 45.6) | 0.349 |
| Female | 67.6 (49.7, 87.8) | 87.1 (63.8, 88.8) | 59.3 (46.7, 77.2) | 63.1 (30.0, 85.3) | 0.413 |
| C3a (ng/mL) | 90,0 (52.3, 120.8) | 61.6 (46.8, 86.8) | 81.4 (47.9, 124.0) | 102.4 (89.4, 158.0) † | 0.019 |
| TCC (mAU/mL) | 2005.5 (1718.6, 2602.9) | 1805.1 (1552.1, 2569.4) | 1938.5 (1724.6, 2310.6) | 2297.5 (2021.5, 3057.8) | 0.051 |
| C1q (μg/mL) | 10.5 (8.2, 13.0) | 10.2 (9.4, 12.6) | 10.3 (8.3, 13.2) | 11.3 (7.3, 13.7) | 0.882 |
| MBL (ng/mL) | 437.3 (167.8, 1498.9) | 694.4 (385.8, 1503.0) | 333.7 (191.0, 1185.8) | 406.4 (138.2, 1564.7) | 0.730 |
| IL-6 (pg/mL) | 5.1 (2.9, 15.0) | 4.4 (1.3, 9.8) | 4.1 (1.9, 6.5) | 11.2 (6.0, 31.7) ‡ | 0.042 |
| CRP (mg/L) | 9.0 (4.0, 20.8) | 12.5 (10.3, 31.8) | 4.0 (2.0, 5.3) † | 22.0 (12.8, 32.5) ‡ | <0.001 |
The data are presented as median and interquartile range. Groups were compared using the Kruskal–Wallis test. † Significant difference in comparison to the no cachexia group. ‡ Significant difference in comparison to the cachexia without inflammation group. BMI: body mass index; HU: Hounsfield unit; L3_IMAT: L3-intermuscular adipose tissue; M-RA: muscle radiation attenuation; L3-SMI: L3-muscle index; L3-VATI: L3-visceral adipose tissue index; L3-SATI: L3-subcutaneous adipose tissue index; TCC: terminal complement complex; C1q: complement component 1q; MBL: mannose binding lectin; IL-6: interleukin 6; CRP: C-reactive protein. mAU/mL: milli arbitrary units/mL.